DK1385551T3 - Antieoplastiske kombinationer indeholdende CCI-779 (rapamycinderivat) sammen med gemcitabin eller fluoruracil - Google Patents

Antieoplastiske kombinationer indeholdende CCI-779 (rapamycinderivat) sammen med gemcitabin eller fluoruracil

Info

Publication number
DK1385551T3
DK1385551T3 DK02726710T DK02726710T DK1385551T3 DK 1385551 T3 DK1385551 T3 DK 1385551T3 DK 02726710 T DK02726710 T DK 02726710T DK 02726710 T DK02726710 T DK 02726710T DK 1385551 T3 DK1385551 T3 DK 1385551T3
Authority
DK
Denmark
Prior art keywords
gemcitabine
neoplastic
fluorouracil
combinations containing
rapamycin derivative
Prior art date
Application number
DK02726710T
Other languages
English (en)
Inventor
Jurgen Hermann Ernst Frisch
James Joseph Gibbons Jr
Gary Dukart
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Priority claimed from PCT/US2002/010912 external-priority patent/WO2002080975A1/en
Application granted granted Critical
Publication of DK1385551T3 publication Critical patent/DK1385551T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02726710T 2001-04-06 2002-04-05 Antieoplastiske kombinationer indeholdende CCI-779 (rapamycinderivat) sammen med gemcitabin eller fluoruracil DK1385551T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28238501P 2001-04-06 2001-04-06
PCT/US2002/010912 WO2002080975A1 (en) 2001-04-06 2002-04-05 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil

Publications (1)

Publication Number Publication Date
DK1385551T3 true DK1385551T3 (da) 2008-12-08

Family

ID=36501707

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02726710T DK1385551T3 (da) 2001-04-06 2002-04-05 Antieoplastiske kombinationer indeholdende CCI-779 (rapamycinderivat) sammen med gemcitabin eller fluoruracil

Country Status (6)

Country Link
US (2) US20020183240A1 (da)
AR (1) AR033012A1 (da)
DK (1) DK1385551T3 (da)
EC (1) ECSP034790A (da)
TW (1) TWI233359B (da)
ZA (1) ZA200308640B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
BRPI0409632A (pt) * 2003-04-22 2006-04-25 Wyeth Corp combinações antineoplásticas
CN102886045A (zh) * 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
AU2016259316B2 (en) * 2005-11-04 2018-09-06 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
EP3488866A1 (en) * 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
DK2275103T3 (da) * 2005-11-21 2014-07-07 Novartis Ag mTor-inhibitorer ved behandling af endokrine tumorer
US20100305150A1 (en) * 2006-02-02 2010-12-02 Novartis Ag Tuberous sclerosis treatment
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20090312360A1 (en) 2008-06-17 2009-12-17 Wyeth Antineoplastic Combinations Containing HKI-272 and Vinorelbine
JP5681108B2 (ja) 2008-08-04 2015-03-04 ワイス・エルエルシー ４−アニリノ−３−シアノキノリンとカペシタビンの抗新生物薬の組合せ
CA2755789C (en) 2009-04-06 2016-01-19 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
IL130908A0 (en) * 1997-01-22 2001-01-28 Univ Texas Tissue-factor (tf) compositions for coagulation and tumor treatment
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
BRPI0409632A (pt) * 2003-04-22 2006-04-25 Wyeth Corp combinações antineoplásticas

Also Published As

Publication number Publication date
ECSP034790A (es) 2003-12-01
US20050187184A1 (en) 2005-08-25
US20020183240A1 (en) 2002-12-05
AR033012A1 (es) 2003-12-03
TWI233359B (en) 2005-06-01
ZA200308640B (en) 2008-04-30

Similar Documents

Publication Publication Date Title
DK1385551T3 (da) Antieoplastiske kombinationer indeholdende CCI-779 (rapamycinderivat) sammen med gemcitabin eller fluoruracil
PT1289985E (pt) Derivados de beta-carbolina uteis como inibidores da fosfodiesterase
HK1060062A1 (en) Antineoplastic combinations comprising cci-779 ( rapamycin derivative) together with gemcitabine or fluorouracil
PT1562902E (pt) Derivados de 2-piridona como inibidores da elastase de neutrofilos
NO2014008I2 (no) Linagliptin
ATE335755T1 (de) Antivirale nukleosidderivate
IL185056A0 (en) Compositions and methods for treating or preventing flaviviridae infections
IL182121A0 (en) Pyrimidine derivatives, processes for the preparation thereof and pharmaceutical compositions containingthe same
BRPI0716971A2 (pt) Uso de 2-6(3-amino-piperini-l-il)-3-metil-2,4-dioxo-3,4-dihidro-2 h-pirimidin-1ilmetil-4-fluoro-benxonitrila
DE602005002992D1 (de) Kippmechanismus und Spiegelsystem
IS8575A (is) 3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra
EP1924684A4 (en) STRUCTURE OF TRANSITION STATUS OF 5'-METHYLTHIOADENOSINE / S-ADENOSYLHOMOCYSTEINE NUCLEOSIDASES
NO20040775L (no) Oftalmisk sammensetning som innbefatter et askomycin
NO20044032L (no) Indolamidderivater med glykogenfosforylase inhibitorisk aktivitet
BR0208566B1 (pt) Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica
FR2884822B1 (fr) Derives de triazines, leur preparation et leur application en therapeutique
DK1663982T3 (da) Aminoquinolinderivater og deres anvendelse som adenosin-A3-ligander
EP1545588A4 (en) METHODS AND COMPOSITIONS FOR ACTIVATION OR INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR D AND VASCULAR ENDOTHELIAL GROWTH FACTOR C
DK1377316T3 (da) Farmaceutisk sammensætning på grundlag af azalider til lokal anvendelse i oftalmologien
MA28847B1 (fr) Derives de pyrrole, leur preparation et leur utilisation en therapeutique
ATE369347T1 (de) Trimere makrocyclisch substituierte halogen- benzolderivate
NO20055180D0 (no) Sammensetninger som innbefatter makrolid T-celle immunomodulerende eller -immunosupressive stoffer i kombinasjon med antibakterielle stoffer
DK1603919T3 (da) 7-Iminoderivater af camptothecin med antitumoraktivitet
UY28661A1 (es) Derivados de cromano
AU2003300544A1 (en) -modified nucleoside derivatives for treating flaviviridae infections